Background {#Sec1}
==========

Obesity is a highly heritable multifactorial disorder defined by a body mass index (BMI) of ≥30 kg/m^2^, which predisposes to many diseases. Rare and common genetic variants associated with obesity identified to date have increased our understanding of the mechanisms by which obesity develops. Copy number variants (CNVs) in a number of chromosomal regions are known to be involved in highly penetrant and individually rare, both isolated and syndromic forms of obesity \[[@CR1]--[@CR3]\]. The latter describes cases where obesity co-occurs with additional phenotypes (e.g., intellectual and developmental disabilities (IDDs), dysmorphism, congenital anomalies) often arising as part of a distinct syndrome, from which Prader-Willi syndrome (PWS; OMIM \#176270) is a classical example. Until recently, only a few genomic disorders other than PWS were known to contribute to increased risk of obesity, including the known microdeletion syndromes 1p36 (OMIM \#607872), 2q37 (OMIM \#600430), 6q16 (*SIM1* gene), 9q34 (OMIM \#610253; *EHMT1* gene), 11p14.1 (OMIM \#612469), and 17p11.2 (OMIM \#182290; *RAI1* gene).

In recent years, however, numerous unique and rare recurring/overlapping CNVs have been associated with a syndromic obesity phenotype in patients through the widespread use of chromosomal microarray analysis (CMA) \[[@CR4]--[@CR16]\]. Examples include deletions of chromosome band 2p25.3 that include the *MYT1L* gene (OMIM \#616521), the recurrent 220-kb deletion of distal 16p11.2 including the *SH2B1* gene (OMIM \#613444), and the recurrent 600-kb 16p11.2 proximal deletion (OMIM \#611913, gene unknown). Also, a novel genomic disorder that causes obesity, ID and seizures has been described in children carrying a recurrent unbalance translocation (8;12)(p23.1;p13.31) that duplicates the *GNB3* gene \[[@CR17]\]. Overlapping 1p21.3 deletions comprising the *DPYD* and *MIR137* genes have been detected in patients with a phenotype consisting primarily of obesity, ID, and autism spectrum disorder (ASD) \[[@CR18], [@CR19]\]. Small 6q16.1 deletions encompassing the *POU3F2* gene were identified in 10 individuals presenting with obesity, hyperphagia and IDDs \[[@CR20]\]. Chromosome 13q34 deletions disrupting the *CHAMP1* gene were linked ID, obesity and mild dysmorphism in five adult individuals \[[@CR21]\].

Syndromic obesity is recognized as an etiologically heterogeneous group of disorders for which an obesity-related genetic change can be identified but only a few genetic causes have been identified to date. Only one study has examined the etiology of syndromic obesity with CMA in a cohort of 100 patients specifically selected for obesity \[[@CR22]\]. In that study, CNVs were regarded either as pathogenic or potentially pathogenic in 22% of cases, and several novel CNVs for which a defined syndrome has not yet been delineated were uncovered. Herein, we report our experience over the past 5 years using CMA to identify CNVs in 279 patients referred with syndromic obesity. This study adds to the current knowledge of CNVs linked to obesity and provides evidence for association with obesity at new and previously identified candidate *loci*.

Methods {#Sec2}
=======

Cohort enrollment and description {#Sec3}
---------------------------------

Only patients who tested negative for PWS (methylation analysis of *SNURF-SNRPN* exon 1 by our laboratory) were included in our study whether or not they had a positive clinical score for PWS. This test population had a mean age of 9 years (range 8 days to 40 years old), 55% of cases represented by male patients (male/female ratio = 1.2). The 2000 Centers for Disease Control and Prevention (CDC) growth charts (available at [https://www.cdc.gov/growthcharts/](https://www.cdc.gov/growthcharts)) were used to plot weight-for-age, height-for-age, weight-for-height, BMI-for-age, and occipito-frontal head circumference (OFC) \[[@CR23]\]. We stratified our cohort into 4 age groups: (1) infants (*n* = 19) \< 2 years old (mean age 13 months; 9 males and 9 females); (2) children (*n* = 153) aged 2--9 years (mean age 6 years; 80 males and 73 females); (3) adolescents (*n* = 98) aged 10--19 years (mean age 9 years; 61 males and 37 females); (4) adults (*n* = 10) \> 20 years old (mean age 27 years; 2 males and 8 females In a majority of patients, recognition of excessive weight gain was based on the following: (1) infants, the standard deviation (SD) of weight-for-height Z-scores \> \~ 1 (mean + 3.23 SD); (2) children and adolescents, BMI-for-age percentiles ≥85th (mean 97.4th and 97.9th percentiles, respectively); (3) adults, BMI values ≥30 kg/m2 (mean 46.7 kg/m2); In 37 patients, data on weight and/or height were missing but they had a documented diagnosis of overweight or obesity made by attending physicians, and 5 other patients aged \< 5 years had hyperphagia with an increase probability of developing obesity. Among a subset of 208 children and adolescents (BMI ≥ 95th percentile), we further classified obesity based on the BMI expressed as a percentage above the 95th BMI percentile according to age and sex, as previously described \[[@CR24], [@CR25]\]: a BMI 100--119% of the 95th percentile was used to define moderate obesity and a BMI ≥120% of the 95th BMI percentile used to define severe obesity. Extreme BMIs were calculated by multiplying the BMI at the 95th percentile by a factor of 1.1 through 1.9 to derive the 110% to 190%, for both genders.

Chromosomal microarray analysis {#Sec4}
-------------------------------

Any of the following genome-wide array platforms were used according to their availability: CytoSure ISCA v2 4x180K (Oxford Gene Technology, Oxford, UK), SurePrint G3 Human CGH 8x60K (Agilent Technologies, Santa Clara, CA), Affymetrix Mapping 100 K and 500 K arrays (Affymetrix, Santa Clara, CA, USA). Most cases (85%) were investigated using high-density oligonucleotide microarrays (4x180K OGT platform). DNA was extracted from peripheral blood using Autopure LS® (Gentra Systems, Inc., Minneapolis, MN). Genomic DNA concentration was measured by Nanodrop spectrophotometer (ThermoFisher). Chromosomal microarray testing was performed according to the manufacturers' instructions. In oligonucleotide-based microarrays, two experiments were performed for each patient sample with reversal of the dye labels for the control and test samples, raw data were processed and analyzed using Agilent Feature Extraction and Genomic Workbench software with the statistical algorithm ADM-2 and sensitivity threshold of 6.7. Affymetrix SNP array data was analyzed with the Genotyping Console (GTC) 4.0 software using default settings and a similarly processed reference sample data set. Due to the limited probe coverage, CNVs on chromosome Y were removed from the analysis. We used the American College of Medical Genetics and Genomics (ACMG) 2011 guidelines for variant interpretation to classify variants in 4 categories: pathogenic CNVs (PCNVs), likely PCNVs, variants of uncertain significance (VUS), and likely benign CNVs \[[@CR26]\]. Healthy and disease variant databases used included the Database of Genomic Variants (DGV, <http://dgv.tcag.ca>), the Online Mendelian Inheritance in Man (OMIM, <https://www.omim.org>/) and the DatabasE of genomiC varIation and Phenotype in Humans using Ensembl Resources (DECIPHER, <http://decipher.sanger.ac.uk>) \[[@CR27]--[@CR29]\]. All genomic breakpoints were based on the human genome build GRCh37 (hg19) (<http://genome.ucsc.edu>/) \[[@CR30]\].

Gene prioritization {#Sec5}
-------------------

Genes affected by the detected CNVs were compared to a list of genes related to obesity downloaded from the Text-mined Hypertension, Obesity and Diabetes candidate gene database (T-HOD) \[[@CR31]\] and the Human Genome Epidemiology encyclopedia Navigator (HUGE, <https://phgkb.cdc.gov/PHGKB>) \[[@CR32]\]. We specifically searched the term "obesity" and retrieved 835 genes annotated in T-HOD and 1920 genes annotated in the HUGE Phenopedia. We also checked the genes affected by CNVs against a list of 370 genes with evidence for playing a role in obesity curated from literature \[[@CR33]\] and a list of 940 genes in the CNV morbidity map for IDDs generated from 29,085 cases and 19,584 controls \[[@CR34]\].

Results {#Sec6}
=======

Cohort and correlation of PCNVs with specific phenotypes {#Sec7}
--------------------------------------------------------

General clinical findings noted in patients are listed in Table [1](#Tab1){ref-type="table"} (individual descriptions are provided in Table S1 in Additional file [1](#MOESM1){ref-type="media"}). Although patients' records were not always complete and clinical comorbidities could not be fully assessed, the most commonly reported features associated with obesity were IDDs, dysmorphism, behavioral phenotypes, hyperphagia, neonatal hypotonia, and language impairments. Hands and feet abnormalities, abnormalities of the external genitalia and eye/vision problems were often reported. Macrocephaly was observed in 92 of 206 (45%) patients, compared to 11 of 206 (5%) patients with microcephaly, and tall stature in 40 of 238 (17%) patients, compared to 22 of 238 (9%) patients with short stature (Z-scores \> or \< ±2 SD). No association was found between these growth parameters in cases with and without PCNVs using the Fisher's Exact test (Fig. [1](#Fig1){ref-type="fig"}).Table 1Additional phenotypes of patients with syndromic obesityClinical featuresTotal cohort (n)Patients with PCNVs (n)Intellectual/developmental disabilities21955Craniofacial dysmorphism14949Behavioral problems13229Hyperphagia11227Infantile hypotonia8832Language impairments8028Hands/ft abnormalities6521Abnormal external genitalia5620Eye/vision problems5116Seizures3113Poor motor skills299Skeletal anomalies239Brain abnormalities197Hearing loss136Cardiac abnormalities104Prevalence could not be assess as complete phenotypic data was not availableFig. 1Comparison of frequencies of each variable among patients with and without PCNVs. The fractions in parentheses indicate the number of cases that manifested the phenotype over the total number of cases with data. *P*-values for the Fisher's exact test are shown. Macro/microcephaly and tall/short stature were defined by the Z-scores \> or \< ±2 SD

In an attempt to determine whether there were phenotypic differences associated with the presence of PCNVs, we compared the frequencies of phenotype pairs segregating together in patients with syndromic obesity caused by PCNVs against those without PCNVs. We constructed a matrix representation (heatmap) of the Chi-square *p*-values between any given pair of phenotypes that co-occurred in patients with and without PCNVs. Out of 133 phenotype pairs that were evaluated (listed in Table S2 in Additional file [2](#MOESM2){ref-type="media"}), 12 had significant associations for PCNVs with *p-*values \< 0.05 (Fig. [2a](#Fig2){ref-type="fig"}). Next, we constructed using Cytoscape \[[@CR35]\] a graphic representation of these phenotype-phenotype associations, where a given pair of phenotype was connected only if they were significant at *p* \< 0.05, to discover the core phenotype variables in the network (those that overlapped most between pairs). The most highly correlated phenotypes are hypotonia, language impairments, abnormalities of the external genitalia, and eye/vision problems. They also correlated with many additional phenotype variables including seizures, sleep problems, tall stature and hands/feet abnormalities (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2The heat map constructed from the *P-*values for the Chi-square statistic test between pairs of phenotypes observed in patients with PCNVs against those without PCNVs is shown at the top, where *P*-values \< 0.05 are represented by small darker gray or black squares and larger values by light gray squares (white squares indicate null values or the absence of association between a given pair of phenotype). Graphical representation of the phenotype network generated using Cytoscape is shown at the bottom, where phenotypes (nodes) are interconnected (edges) if they had significant associations for PCNVs at *P* \< 0.05. The resulting network has 10 interconnected phenotypes and 8 not connected phenotype variables. Red nodes and edges highlight the most highly connected phenotypes and their interactions in the network

Characterization of CNVs in patients with syndromic obesity {#Sec8}
-----------------------------------------------------------

Overall, CMA identified clinically relevant genomic imbalances in 22% of patients, potentially clinically relevant CNVs in 2%, VUS in 5% and likely benign CNVs in 11% (Table [2](#Tab2){ref-type="table"}). All clinically relevant results per individual are listed in Table [3](#Tab3){ref-type="table"}. The genomic regions associated with likely PCNVs, VUS and likely benign CNVs are listed in Additional file [3](#MOESM3){ref-type="media"}: Table S3.Table 2Overall findings of microarray testingNumber%Total number of cases279--With imbalances11240With pathogenic CNVs6122*With Known syndromes4717*Pathogenic imbalances ^a^68-- Del4972 Dup1928  \> 5 Mb2131 De novo3049 Inherited610 Unknown1931 Not maternal610With likely pathogenic CNVs62With CNVs of uncertain significance155With likely benign CNVs3011^a^Pathogenic imbalances included 45 simple deletions or duplications, 4 unbalanced translocations, an insertional translocation, and 6 other complex rearrangements believed to have been formed from the same rearrangement. In the remaining 5 patients, the rearrangements were associated with a second-site CNV arisen apparently independent which were classified as benign or of uncertain significanceTable 3Pathogenic copy number variations (PCNVs) detected in 279 patients with syndromic obesityCase numberAgeGenderWeight StatusCNV TypeCytobandGenome CoordinateSizeOriginClinical significanceRefSeq genes*Genomic imbalance disorders* **P1**5yFReferred as obeseDel1p36.33734595-19708651236270Unk1p36 terminal deletion***[KLHL17]{.smallcaps}*** *[,]{.smallcaps}* [[AGRN]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TAS1R3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DVL1]{.smallcaps}*** *[,]{.smallcaps}* ***[VWA1]{.smallcaps}*** *[,]{.smallcaps}* ***[MMP23B]{.smallcaps}*** *[,]{.smallcaps}* ***[GABRD]{.smallcaps}*** **P2**34yFBMI 59.1Del1p36.33734595-22233171488722Unk1p36 terminal deletion, complex***[KLHL17]{.smallcaps}*** *[,]{.smallcaps}* [[AGRN]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TAS1R3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DVL1]{.smallcaps}*** *[,]{.smallcaps}* ***[VWA1]{.smallcaps}*** *[,]{.smallcaps}* ***[MMP23B, GABRD,]{.smallcaps}*** [[PRKCZ]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SKI]{.smallcaps}]{.ul} ***[\*]{.smallcaps}***Dup1p36.33\
p36.322225679-2694799469120\-- **P3**14yFBMI 26.8 (93.3th)Del1p36.33\
p36.32794592-23772691582677De novo1p36 terminal deletion***[KLHL17]{.smallcaps}*** *[,]{.smallcaps}* [[AGRN]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TAS1R3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DVL1]{.smallcaps}*** *[,]{.smallcaps}* ***[VWA1]{.smallcaps}*** *[,]{.smallcaps}* ***[MMP23B]{.smallcaps}*** *[,]{.smallcaps}* ***[GABRD,]{.smallcaps}*** [[PRKCZ]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SKI]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P4**6yFBMI 19.7 (96.8th)Del1p36.33\
p36.32734595-35310402796445Unk1p36 terminal deletion***[KLHL17]{.smallcaps}*** *[,]{.smallcaps}* [[AGRN]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TAS1R3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DVL1]{.smallcaps}*** *[,]{.smallcaps}* ***[VWA1]{.smallcaps}*** *[,]{.smallcaps}* ***[MMP23B]{.smallcaps}*** *[,]{.smallcaps}* ***[GABRD,]{.smallcaps}*** [[PRKCZ]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SKI]{.smallcaps}]{.ul} ***[,\*]{.smallcaps}*** [[TNFRSF14]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PRDM16]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P5**11yMBMI 30.8 (99th)Del1p36.31\
p36.226204969-94331183228149Unk1p36 interstitial deletion[[CAMTA1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PER3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[UTS2]{.smallcaps}]{.ul} *[, RERE,]{.smallcaps}* [[H6PD]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P6**15yFBMI 37.1 (99.1th)Del1p22.1\
p21.293919217-998461765926959De novo1p21.3 deletion[[F3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PTBP2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DPYD]{.smallcaps}*** *[,]{.smallcaps}* ***[MIR137]{.smallcaps}*** **P7**8yFBMI 33.2 (99.7th)Del1p21.3\
p13.395696444-10775587912059435Unk1p21.3 deletion[[PTBP2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DPYD]{.smallcaps}*** *[,]{.smallcaps}* ***[MIR137]{.smallcaps}*** *[,]{.smallcaps}* [[VCAM1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* COL11A1]{.smallcaps}*** *[,]{.smallcaps}* [[AMY2B]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[AMY2A]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[AMY1A]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P8**6yMBMI 28.8 (99.9th)Dup1q21.1146074084-1478280291753945Unk1q21.1 distal duplication[[PRKAB2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[CHD1L]{.smallcaps}*** *[,]{.smallcaps}* ***[GJA5]{.smallcaps}*** *[,]{.smallcaps}* ***[GJA8]{.smallcaps}*** **P9**7yFBMI 22.6 (98.2th)Del2p25.363452-32155933152141De novo2p25.3 terminal deletion[[ACP1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[TMEM18]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* SNTG2]{.smallcaps}*** *[,]{.smallcaps}* [[TPO]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* MYT1L]{.smallcaps}*** **P10**8yFBMI 29.1 (99.5th)Del2q37.2\
q37.3237220842-2429958355774993De novo2q37 terminal deletion[[PRLH]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[LRRFIP1]{.smallcaps}]{.ul} [,]{.smallcaps} [[PER2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[HDAC4]{.smallcaps}*** *[,]{.smallcaps}* [[GPC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CAPN10]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GPR35]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* KIF1A]{.smallcaps}*** *[,]{.smallcaps}* [[PASK]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STK25]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P11**21yMReferred as obeseDel2q37.2\
q37.3236854160-2429958356141675Unk2q37 terminal deletion***[AGAP1]{.smallcaps}*** *[,]{.smallcaps}* [[PRLH]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[LRRFIP1]{.smallcaps}]{.ul} [,]{.smallcaps} [[PER2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[HDAC4]{.smallcaps}*** *[,]{.smallcaps}* [[GPC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CAPN10]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GPR35]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* KIF1A]{.smallcaps}*** *[,]{.smallcaps}* [[PASK]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STK25]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P12**10yMBMI 29.8 (99th)Del2q37.2\
q37.3236944801-2430146306069829De novo2q37 terminal deletion, complex***[AGAP1]{.smallcaps}*** *[,]{.smallcaps}* [[PRLH]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[LRRFIP1]{.smallcaps}]{.ul} [,]{.smallcaps} [[PER2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[HDAC4]{.smallcaps}*** *[,]{.smallcaps}* [[GPC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CAPN10]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GPR35]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* KIF1A]{.smallcaps}*** *[,]{.smallcaps}* [[PASK]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STK25]{.smallcaps}]{.ul} ***[\*]{.smallcaps}***Dup2q37.1\
q37.2235090417-2368029301712513\-- **P13**9yFBMI 24.7 (98.2th)Del2q37.1\
q37.3234850276-2430283358178059Unk2q37 terminal deletion, complex[[TRPM8]{.smallcaps}]{.ul} ***[, AGAP1]{.smallcaps}*** *[,]{.smallcaps}* [[PRLH]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[LRRFIP1]{.smallcaps}]{.ul} [,]{.smallcaps} [[PER2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[HDAC4]{.smallcaps}*** *[,]{.smallcaps}* [[GPC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CAPN10]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GPR35]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* KIF1A]{.smallcaps}*** *[,]{.smallcaps}* [[PASK]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STK25]{.smallcaps}]{.ul} ***[\*]{.smallcaps}***Dup2q37.1233867403-234794816927413[[UTG1A1]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P14**5yFBMI 24.0 (99.7th)Del2q37.3240880562-2429480602067498UnkUnbalanced translocation[[GPC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CAPN10]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GPR35]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* KIF1A]{.smallcaps}*** *[,]{.smallcaps}* [[PASK]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STK25]{.smallcaps}]{.ul} ***[\*]{.smallcaps}***Dup17q25.378709250-810362612327011[[RPTOR]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ACTG1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GCGR]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[PCYT2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[FASN]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CSNK1D]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[UTS2R]{.smallcaps}]{.ul} **P15**10yMBMI 31.0 (99.3th)Del6q16.1\
q2195836632-10801094012174308De novo6q16 deletion[[KLHL32]{.smallcaps}]{.ul} *[, POU3F2,]{.smallcaps}* [[MCHR2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[SIM1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GRIK2]{.smallcaps}*** *[,]{.smallcaps}* [[LIN28B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ATG5]{.smallcaps}]{.ul} **P16**15yFBMI 40.5 (99.4th)Del7q11.2372420782-749856442564862Unk7q11.23 deletion***[FKBP6]{.smallcaps}*** *[,]{.smallcaps}* ***[FZD9]{.smallcaps}*** *[,]{.smallcaps}* [[BCL7B]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TBL2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[MLXIPL]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STX1A]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CLDN3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[ELN]{.smallcaps}*** *[,]{.smallcaps}* ***[LIMK1]{.smallcaps}*** *[,]{.smallcaps}* [[RFC2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* CLIP2]{.smallcaps}*** *[,]{.smallcaps}* ***[GTF2IRD1]{.smallcaps}*** *[,]{.smallcaps}* ***[GTF2I]{.smallcaps}*** *[,]{.smallcaps}* ***[NCF1]{.smallcaps}*** **P17**6yMBMI 30.6 (99.9th)Del7q11.2372437606-750537872616181Unk7q11.23 deletion***[FKBP6]{.smallcaps}*** *[,]{.smallcaps}* ***[FZD9]{.smallcaps}*** *[,]{.smallcaps}* [[BCL7B]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TBL2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[MLXIPL]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[STX1A]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CLDN3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[ELN]{.smallcaps}*** *[,]{.smallcaps}* ***[LIMK1]{.smallcaps}*** *[,]{.smallcaps}* [[RFC2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* CLIP2]{.smallcaps}*** *[,]{.smallcaps}* ***[GTF2IRD1]{.smallcaps}*** *[,]{.smallcaps}* ***[GTF2I]{.smallcaps}*** *[,]{.smallcaps}* ***[NCF1]{.smallcaps}*** **P18**6yMBMI 33.4 (99.9th)Del8p23.3\
p23.1176464-77867597610295De novoUnbalanced translocation***[CLN8]{.smallcaps}*** *[,]{.smallcaps}* [[CSMD1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[DEFA1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DEFB103A]{.smallcaps}*** *[,]{.smallcaps}* ***[DEFB103B]{.smallcaps}*** *[,]{.smallcaps}* ***[DEFB104A]{.smallcaps}*** *[,]{.smallcaps}* ***[DEFB106A]{.smallcaps}*** *[,]{.smallcaps}* ***[DEFB105A]{.smallcaps}*** *[,]{.smallcaps}* ***[DEFB107A]{.smallcaps}*** *[,]{.smallcaps}* ***[DEFB4A]{.smallcaps}***Dup12p13.33\
p13.31204618-83094738104855***[SLC6A13]{.smallcaps}*** *[,]{.smallcaps}* [[WNT5B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ADIPOR2,]{.smallcaps}]{.ul} ***[\* CACNA2D4]{.smallcaps}*** *[,]{.smallcaps}* ***[CACNA1C]{.smallcaps}*** *[,]{.smallcaps}* [[FOXM1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TEAD4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PARP11]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[KCNA1]{.smallcaps}*** *[,]{.smallcaps}* [[NTF3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[VWF]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TNFRSF1A]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[SCNN1A]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GAPDH]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CD4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GNB3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CD163]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[APOBEC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GDF3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SLC2A14]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[C3AR1]{.smallcaps}]{.ul} **P19**6yMBMI 25.8 (99.8th)Dup8p23.18054556-119853563930800Not mat8p23.1 duplication***[CLDN23]{.smallcaps}*** *[,]{.smallcaps}* [[MFHAS1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PPP1R3B]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[LOC157273]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TNKS]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[MSRA]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* SOX7]{.smallcaps}*** *[,]{.smallcaps}* [[MTMR9]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[BLK]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GATA4]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* NEIL2]{.smallcaps}*** *[,]{.smallcaps}* [[FDFT1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CTSB]{.smallcaps}]{.ul}Dup13q12.1223706634-249107651204131Not matUncertain*[SGCG,]{.smallcaps}* ^***[¶]{.smallcaps}***^ ***[SACS,]{.smallcaps}*** *[MIPEP]{.smallcaps}* **P20**11yFBMI 26.7 (97.6th)Del9p24.3\
p22.340910-1430497314264063De novo9p terminal deletion***[KANK1]{.smallcaps}*** *[,]{.smallcaps}* ***[DMRT1]{.smallcaps}*** *[,]{.smallcaps}* [[SMARCA2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[VLDLR]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GLIS3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[JAK2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[RLN1]{.smallcaps}*** *[,]{.smallcaps}* [[IL33]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[KDM4C]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PTPRD]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P21**12mFWeight-for Height +1sdDel9p24.3\
p22.3204149-1526043915056290De novo9p terminal deletion***[KANK1]{.smallcaps}*** *[,]{.smallcaps}* ***[DMRT1]{.smallcaps}*** *[,]{.smallcaps}* [[SMARCA2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[VLDLR]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GLIS3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[JAK2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[RLN1]{.smallcaps}*** *[,]{.smallcaps}* [[IL33]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[KDM4C]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PTPRD,]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** [[TTC39B]{.smallcaps}]{.ul} **P22**17yMBMI 28.7 (95.7th)Del9p24.3\
p22.3201149-88075938606444Unk9p terminal deletion***[KANK1]{.smallcaps}*** *[,]{.smallcaps}* ***[DMRT1]{.smallcaps}*** *[,]{.smallcaps}* [[SMARCA2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[VLDLR]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[GLIS3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[JAK2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[RLN1]{.smallcaps}*** *[,]{.smallcaps}* [[IL33]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[KDM4C]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PTPRD]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P23**9yFBMI 31.1 (99.5th)Del9q34.3140665414-141018984353570De novo9q34.3 deletion[[EHMT1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* CACNA1B]{.smallcaps}*** **P24**14yMBMI 28.7 (97.6th)Del13q12.3\
q13.129081250-335293104448060De novo13q12.3 deletion*[POMP]{.smallcaps}* [,]{.smallcaps} *[SLC46A3]{.smallcaps}* [,]{.smallcaps} *[MTUS2]{.smallcaps}* [,]{.smallcaps} *[SLC7A1]{.smallcaps}* [,]{.smallcaps} *[UBL3,]{.smallcaps}* [[KATNAL1]{.smallcaps}]{.ul} *[, LINC00426, HMGB1,]{.smallcaps}* ***[ALOX5AP]{.smallcaps}*** *[,]{.smallcaps}* ***[\*]{.smallcaps}*** *[RXFP2,]{.smallcaps}* ***[BRCA2\*]{.smallcaps}*** **P25**8yMBMI 25.4 (99.2th)Del15q11.222729423-23086969357546Unk15q11.2 microdeletion***[NIPA1]{.smallcaps}*** *[,]{.smallcaps}* ***[NIPA2]{.smallcaps}*** *[,]{.smallcaps}* ***[CYFIP1]{.smallcaps}*** **P26**10yFBMI 22.1 (93.4th)Del16p13.12\
p13.1114780302-164007741620472Pat16p13.1 deletion[[NDE1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[MYH11]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ABCC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ABCC6]{.smallcaps}]{.ul} **P27**4yFHyperphagiaDup16p13.12\
p13.1114796004-165869411790937Pat16p13.1 duplication[[NDE1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[MYH11]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ABCC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ABCC6]{.smallcaps}]{.ul} **P28**7yFBMI 20.5 (96.6th)Del16p11.228843754-29044850201096De novo16p11.2 (BP 2-3) deletion[[ATXN2L]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[TUFM]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[MIR4721]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SH2B1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ATP2A1]{.smallcaps}]{.ul} ***[,\*]{.smallcaps}*** [[SPNS1]{.smallcaps}]{.ul} **P29**12yMBMI 30.4 (98.8th)Del16p11.229592751-30197466604715Not mat16p11.2 (BP 4-5) deletion***[QPRT]{.smallcaps}*** *[,]{.smallcaps}* ***[PRRT2]{.smallcaps}*** *[,]{.smallcaps}* ***[SEZ6L2]{.smallcaps}*** *[,]{.smallcaps}* ***[DOC2A]{.smallcaps}*** *[,]{.smallcaps}* ***[ALDOA]{.smallcaps}*** *[,]{.smallcaps}* ***[TBX6]{.smallcaps}*** *[,]{.smallcaps}* [[MAPK3]{.smallcaps}]{.ul} **P30**8yMReferred as obeseDup16p11.229592751-30197466604715Pat16p11.2 (BP 4-5) duplication***[QPRT]{.smallcaps}*** *[,]{.smallcaps}* ***[PRRT2]{.smallcaps}*** *[,]{.smallcaps}* ***[SEZ6L2]{.smallcaps}*** *[,]{.smallcaps}* ***[DOC2A]{.smallcaps}*** *[,]{.smallcaps}* ***[ALDOA]{.smallcaps}*** *[,]{.smallcaps}* ***[TBX6]{.smallcaps}*** *[,]{.smallcaps}* [[MAPK3]{.smallcaps}]{.ul} **P31**11yMBMI 42.2 (99.7th)Del17p11.217006987-201713573164370De novo17p11.2 deletion***[COPS3]{.smallcaps}*** *[,]{.smallcaps}* ***[NT5M]{.smallcaps}*** *[,]{.smallcaps}* ***[MED9]{.smallcaps}*** *[,]{.smallcaps}* [[PEMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* RAI1]{.smallcaps}*** *[,]{.smallcaps}* [[SREBF1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* ATPAF2]{.smallcaps}*** *[,]{.smallcaps}* ***[DRG2]{.smallcaps}*** *[,]{.smallcaps}* ***[SMCR8]{.smallcaps}*** *[,]{.smallcaps}* [[MFAP4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SLC47A1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ALDH3A2,]{.smallcaps}]{.ul} ***[SPECC1]{.smallcaps}*** **P32**6yMBMI 31.2 (99.9th)Del17p11.216757563-203955353637972Not mat17p11.2 deletion[[TNFRSF13B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[COPS3]{.smallcaps}*** *[,]{.smallcaps}* ***[NT5M]{.smallcaps}*** *[,]{.smallcaps}* ***[MED9]{.smallcaps}*** *[,]{.smallcaps}* [[PEMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* RAI1]{.smallcaps}*** *[,]{.smallcaps}* [[SREBF1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* ATPAF2]{.smallcaps}*** *[,,]{.smallcaps}* ***[DRG2]{.smallcaps}*** *[,]{.smallcaps}* ***[SMCR8]{.smallcaps}*** *[,]{.smallcaps}* [[MFAP4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SLC47A1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ALDH3A2,]{.smallcaps}]{.ul} ***[SPECC1]{.smallcaps}*** **P33**7yFBMI 21.9 (97.9th)Del17p11.216603145-203955353792390De novo17p11.2 deletion[[TNFRSF13B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[COPS3]{.smallcaps}*** *[,]{.smallcaps}* ***[NT5M]{.smallcaps}*** *[,]{.smallcaps}* ***[MED9]{.smallcaps}*** *[,]{.smallcaps}* [[PEMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* RAI1]{.smallcaps}*** *[,]{.smallcaps}* [[SREBF1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* ATPAF2]{.smallcaps}*** *[,]{.smallcaps}* ***[DRG2]{.smallcaps}*** *[,]{.smallcaps}* ***[SMCR8]{.smallcaps}*** *[,]{.smallcaps}* [[MFAP4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SLC47A1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ALDH3A2,]{.smallcaps}]{.ul} ***[SPECC1]{.smallcaps}*** **P34**8yFBMI 25.9 (98.9th)Del17p11.216603145-203955353792390Unk17p11.2 deletion[[TNFRSF13B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[COPS3]{.smallcaps}*** *[,]{.smallcaps}* ***[NT5M]{.smallcaps}*** *[,]{.smallcaps}* ***[MED9]{.smallcaps}*** *[,]{.smallcaps}* [[PEMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* RAI1]{.smallcaps}*** *[,]{.smallcaps}* [[SREBF1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* ATPAF2]{.smallcaps}*** *[,]{.smallcaps}* ***[DRG2]{.smallcaps}*** *[,]{.smallcaps}* ***[SMCR8]{.smallcaps}*** *[,]{.smallcaps}* [[MFAP4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SLC47A1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ALDH3A2,]{.smallcaps}]{.ul} ***[SPECC1]{.smallcaps}*** **P35**10yMBMI 28.1 (99th)Del17p11.216603145-204633993860254De novo17p11.2 deletion[[TNFRSF13B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[COPS3]{.smallcaps}*** *[,]{.smallcaps}* ***[NT5M]{.smallcaps}*** *[,]{.smallcaps}* ***[MED9]{.smallcaps}*** *[,]{.smallcaps}* [[PEMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* RAI1]{.smallcaps}*** *[,]{.smallcaps}* [[SREBF1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* ATPAF2]{.smallcaps}*** *[,]{.smallcaps}* ***[DRG2]{.smallcaps}*** *[,]{.smallcaps}* ***[SMCR8]{.smallcaps}*** *[,]{.smallcaps}* [[MFAP4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SLC47A1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ALDH3A2,]{.smallcaps}]{.ul} ***[SPECC1]{.smallcaps}*** **P36**9yMBMI 22.2 (96.8th)Dup17q21.31\
q21.3240993738-451667864173048De novo17q21.3 duplication[[AOC3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[G6PC]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[BRCA1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* SOST]{.smallcaps}*** *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[PPY]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[PYY]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[TMEM101]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[HDAC5]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ITGA2B]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[EFTUD2]{.smallcaps}*** *[,]{.smallcaps}* [[PLCD3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CRHR1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* MAPT]{.smallcaps}*** *[,]{.smallcaps}* ***[KANSL1]{.smallcaps}*** **P37**8yFBMI 22.3 (97.4th)Dup19p13.212640509-13231703591194Unk19p13.2 duplication*[MAST1, CALR,]{.smallcaps}* ***[NFIX]{.smallcaps}***Dup9p22.119066513-19497724431211UnkUncertain[[PLIN2]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P38**18yFBMI 41.5 (99th)Del19p13.1214384925-160345841649659De novo19p13.12 deletion*[CD97, DDX39A]{.smallcaps}* ***[,]{.smallcaps}*** *[PKN1]{.smallcaps}* [,]{.smallcaps} *[PTGER1, GIPC1, CASP14,]{.smallcaps}* ***[NOTCH3,]{.smallcaps}*** [[CYP4F11]{.smallcaps}]{.ul} **P39**8yFReferred as obeseDel22q11.2118890162-203115541421392De novo22q11.2 deletion***[PRODH]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR2]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR14]{.smallcaps}*** *[,]{.smallcaps}* ***[CDC45]{.smallcaps}*** *[,]{.smallcaps}* [[TBX1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GNB1L]{.smallcaps}*** *[,]{.smallcaps}* [[TXNRD2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[COMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DGCR8]{.smallcaps}*** *[,]{.smallcaps}* ***[ZDHHC8]{.smallcaps}*** **P40**3yMBMI 34.7 (99.9th)Del22q11.2118661758-216847983023040De novo22q11.2 deletion***[PRODH]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR2]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR14]{.smallcaps}*** *[,]{.smallcaps}* ***[CDC45]{.smallcaps}*** *[,]{.smallcaps}* [[TBX1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GNB1L]{.smallcaps}*** *[,]{.smallcaps}* [[TXNRD2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[COMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DGCR8]{.smallcaps}*** *[,]{.smallcaps}* ***[ZDHHC8]{.smallcaps}*** *[,]{.smallcaps}* ***[PI4KA,]{.smallcaps}*** [[SLC74A]{.smallcaps}]{.ul} **P41**9yMBMI 32.5 (99.6th)Del22q11.2118661758-216847983023040De novo22q11.2 deletion***[PRODH]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR2]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR14]{.smallcaps}*** *[,]{.smallcaps}* ***[CDC45]{.smallcaps}*** *[,]{.smallcaps}* [[TBX1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GNB1L]{.smallcaps}*** *[,]{.smallcaps}* [[TXNRD2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[COMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DGCR8]{.smallcaps}*** *[,]{.smallcaps}* ***[ZDHHC8]{.smallcaps}*** *[,]{.smallcaps}* ***[PI4KA,]{.smallcaps}*** [[SLC74A]{.smallcaps}]{.ul} **P42**13mMWeight-for Height +1sdDel22q11.2118818429-216614362843007Pat22q11.2 deletion***[PRODH]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR2]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR14]{.smallcaps}*** *[,]{.smallcaps}* ***[CDC45]{.smallcaps}*** *[,]{.smallcaps}* [[TBX1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GNB1L]{.smallcaps}*** *[,]{.smallcaps}* [[TXNRD2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[COMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DGCR8]{.smallcaps}*** *[,]{.smallcaps}* ***[ZDHHC8]{.smallcaps}*** *[,]{.smallcaps}* ***[PI4KA,]{.smallcaps}*** [[SLC74A]{.smallcaps}]{.ul} **P43**18yMReferred as obeseDup22q11.2118890162-214640562573894Pat22q11.2 duplication***[PRODH]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR2]{.smallcaps}*** *[,]{.smallcaps}* ***[DGCR14]{.smallcaps}*** *[,]{.smallcaps}* ***[CDC45]{.smallcaps}*** *[,]{.smallcaps}* [[TBX1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GNB1L]{.smallcaps}*** *[,]{.smallcaps}* [[TXNRD2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[COMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* DGCR8]{.smallcaps}*** *[,]{.smallcaps}* ***[ZDHHC8]{.smallcaps}*** *[,]{.smallcaps}* ***[PI4KA,]{.smallcaps}*** [[SLC74A]{.smallcaps}]{.ul} **P44**5yMBMI 27.9 (99.9th)Del22q11.21\
q11.2321759572-238229252063353Unk22q11.2 deletion, distal***[HIC2,]{.smallcaps}*** [[MAPK1,]{.smallcaps}]{.ul} ***[\* GNAZ]{.smallcaps}*** *[,]{.smallcaps}* ***[BCR]{.smallcaps}*** **P45**7yFBMI 24.8 (98.9th)Del22q11.21\
q11.2221468437-229596091491172Not mat22q11.2 deletion, distal***[HIC2]{.smallcaps}*** *[,]{.smallcaps}* [[MAPK1]{.smallcaps}]{.ul} ***[\*]{.smallcaps}***Dup3p26.3857110-1414719557609Not matUncertain[\--]{.smallcaps} **P46**2yFBMI 17.7 (85th)Del22q11.22\
q11.2323012069-23648827636758Mat22q11.2 deletion, distal***[GNAZ]{.smallcaps}*** *[,]{.smallcaps}* ***[BCR]{.smallcaps}*** **P47**15yMBMI 39.5 (99.6th)Del22q11.22\
q11.2323063178-23696464633286Unk22q11.2 deletion, distal***[GNAZ]{.smallcaps}*** *[,]{.smallcaps}* ***[BCR]{.smallcaps}****Other pathogenic imbalances* **P48**2yMBMI 24.4 (99.9th)Del3p26.373603-12733001199697De novoUnbalanced translocation***[CHL1]{.smallcaps}***Dup11q22.3\
q25106251478-13466866528417187[[ACAT1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ATM]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[POU2AF1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IL18]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ANKK1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[DRD2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[HTR3B, HTR3A]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[NNMT]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[BUD13]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[APOA5]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[APOA4]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[APOC3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[APOA1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[BACE1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IL10RA]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CD3E]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[HYOU1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[H2AFX]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CBL]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[USP2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[THY1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ARHGEF12]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[BSX]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[HSPA8]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CLMP]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[NRGN]{.smallcaps}*** *[,]{.smallcaps}* [[SLC37A2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TIRAP]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[KCNJ1]{.smallcaps}*** *[,]{.smallcaps}* [[KCNJ5]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[OPCML]{.smallcaps}]{.ul} **P49**14yFReferred as obeseDel3p24.128719852-301699711450119UnkComplex rearrangement*[LINC00693, RBMS3-AS3, RBMS3]{.smallcaps}* [,]{.smallcaps} *[RBMS3-AS1]{.smallcaps}*Dup3q11.2\
q13.3193558505-11589038422331879[[EPHA6]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ARL6]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[STG3GAL6]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[COL8A1]{.smallcaps}*** *[,]{.smallcaps}* [[CCDC80]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[BOC]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ZDHHC23]{.smallcaps}]{.ul} *[, ZBTB20]{.smallcaps}* [,]{.smallcaps} *[GAP43, LSAMP,]{.smallcaps}* [[DRD3]{.smallcaps}]{.ul} **P50**10yMBMI 30.4 (99.3th)Del3q25.33159252702-1605552171302515De novoUncertain[[IL12A]{.smallcaps}]{.ul}Del13q31.2\
q32.189522636-950653105542674De novoFeingold syndrome***[MIR17HG]{.smallcaps}*** *[,]{.smallcaps}* [[GPC5]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* GPC6]{.smallcaps}*** **P51**14yFBMI 27.9 (95.8th)Del7q22.1\
q22.3102358320-1054876553129335De novoClinically relevant[[NAPEPLD]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[RELN]{.smallcaps}*** *[,]{.smallcaps}* [[LHFPL3]{.smallcaps}]{.ul} **P52**2yFBMI 27.0 (99.9th)Del10p15.3\
p14269695-1157954611309851De novoUnbalanced translocation***[ZMYND11]{.smallcaps}*** *[,]{.smallcaps}* [[DIP2C]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[IDI1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ADRAB2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PFKP]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[KLF6]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ARK1C1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[AKR1C2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ARK1C3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[AKR1C4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[UCN3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IL15RA]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IL2RA]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[PFKFB3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PRKCQ]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[GATA3]{.smallcaps}***Dup6q27169505179-1706944861189307*[WDR27]{.smallcaps}* **P53**5mFReferred as obeseDup10p15.3\
p12.31119794-1950958519389791Not matComplex rearrangement***[ZMYND11]{.smallcaps}*** *[,]{.smallcaps}* [[DIP2C]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[IDI1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ADRAB2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PFKP]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[KLF6]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ARK1C1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[AKR1C2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ARK1C3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[AKR1C4]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[UCN3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IL15RA]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IL2RA]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[PFKFB3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PRKCQ]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[GATA3,]{.smallcaps}*** [[CDC123]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CAMK1D]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CCDC3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PTER]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CUBN]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[MRC1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CACNB2]{.smallcaps}]{.ul}Dup13q11\
q12.319440913-3103190711590994Not mat***[TUBA3C]{.smallcaps}*** *[,]{.smallcaps}* ***[GJB2]{.smallcaps}*** *[,]{.smallcaps}* ***[CRYL1]{.smallcaps}*** *[, SGCG,]{.smallcaps}* ***[SACS,]{.smallcaps}*** *[MIPEP,]{.smallcaps}* [[GPR12]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GTF3A]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[MTIF3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\* POLR1D]{.smallcaps}*** *[,]{.smallcaps}* [[PDX1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[CDX2]{.smallcaps}]{.ul} *[, POMP]{.smallcaps}* [,]{.smallcaps} *[SLC46A3]{.smallcaps}* [,]{.smallcaps} *[MTUS2]{.smallcaps}* [,]{.smallcaps} *[SLC7A1]{.smallcaps}* [,]{.smallcaps} *[UBL3,]{.smallcaps}* [[KATNAL1,]{.smallcaps}]{.ul} *[LINC00426]{.smallcaps}* **P54**9yFBMI 34.3 (99.7th)Dup10q26.11\
q26.3120306959-13543440915127450De novo10qter duplication[[PRLHR]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[PRDX3]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[BAG3]{.smallcaps}*** *[,]{.smallcaps}* [[WDR11]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[FGFR2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[ACADSB]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[BUB3]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[OAT]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TCERG1L]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PRAP1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[CYP2E1]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P55**7yFBMI 23.6 (98.8th)Del12q15\
q21.170555659-731531912597532De novoClinically relevant[[PTPRB]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[TSPAN8]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[LGR5TPH2]{.smallcaps}]{.ul} **P56**13yFBMI 36.8 (99.4th)Dup12q21.32\
q23.188684581-10146485912780278De novoInsertional translocation[[KITLG]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[ATP2B1]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[SOCS2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[LTA4H]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[RMST]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[NR1H4]{.smallcaps}]{.ul} ***[\*]{.smallcaps}*** **P57**15yMBMI 43.1 (99.7th)Del13q33.2\
q34106648660-1151056558456995Not mat13qter deletion***[EFNB2]{.smallcaps}*** *[,]{.smallcaps}* [[MYO16]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[IRS2]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[COL4A1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[ARHGEF7]{.smallcaps}*** *[,]{.smallcaps}* [[F7]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[GAS6]{.smallcaps}]{.ul} *[, CHAMP1]{.smallcaps}* **P58**4yMBMI 22.0 (99.9th)Dup14q11.221244696-222508791006183De novo14q11.2 microduplication***[SUPT16H]{.smallcaps}*** *[,]{.smallcaps}* ***[CHD8]{.smallcaps}*** **P59**16yFBMI 38.5 (99th)Del14q1229781404-30552936771532De novo14q12 deletion, non-critical[[PRKD1]{.smallcaps}]{.ul} ***[\*]{.smallcaps}***Dup4p16.110068064-10529023460959MatLikely benign***[WDR1]{.smallcaps}*** **P60**7yFBMI 24.8 (99.3th)DelXp22.12\
p22.1318214020-198336341619614UnkRett syndrome-like***[CDKL5]{.smallcaps}*** *[,]{.smallcaps}* ***[RS1]{.smallcaps}*** *[,]{.smallcaps}* [[PHKA2]{.smallcaps}]{.ul} *[,]{.smallcaps}* [[PDHA1]{.smallcaps}]{.ul} *[,]{.smallcaps}* ***[\*]{.smallcaps}*** [[SH3KBP1]{.smallcaps}]{.ul} **P61**14yMBMI 37.0 (99.5th)DupXp22.375943-26856052609662De novoComplex rearrangement***[SHOX]{.smallcaps}*** [,]{.smallcaps} ***[ASMTL]{.smallcaps}*** [,]{.smallcaps} ***[ASMT]{.smallcaps}***DupXq21.31\
q21.3288489522-923573533867831*[TGIF2 LX]{.smallcaps}* [,]{.smallcaps} *[PABPC5-AS1]{.smallcaps}* [,]{.smallcaps} *[PABPC5]{.smallcaps}* [,]{.smallcaps} *[PCDH11X]{.smallcaps}Abbreviations: M* male, *F* female, *Del* deletion, *Dup* duplication, *y* years, *m* months, *BMI* body mass index, *SD* standard deviation, *unk* unknown, *mat* maternally inherited, *pat* paternally inherited, *not mat* not maternally inherited; Genes in bold were listed in the CNV morbidity map of IDDs \[[@CR34]\]. Underlined genes were retrieved from the Text-mined Hypertension, Obesity and Diabetes candidate gene database (T-HOD), the Human Genome Epidemiology (HUGE) Phenopedia, and from a list of obesity candidate genes curated from the literature \[[@CR33]\]. Genes found at the intersection of at least two gene sets are highlighted (asterisks). Patients 6-12, 14, 15, 18, 23, 28, 30-33, 35, 40-43, 46-48, 51, 52, 55, 56, 58-60) have been published previously as separate studies \[[@CR36]-[@CR38]\]

### Pathogenic CNVs {#Sec9}

A total of 68 pathogenic imbalances were detected in 61 patients, the majority of which pathogenic deletions (72%) and rearrangements smaller than 5-Mb (70%). 31 of the patients (6--12, 14, 15, 18, 23, 28, 30--33, 35, 40--43, 46--48, 51, 52, 55, 56, 58--60) had previously been published as separate studies \[[@CR36]--[@CR38]\]. De novo PCNVs were found in 30 patients, whereas only 6 patients inherited a pathogenic deletion or duplication from an apparently unaffected parent, all of which occurring at genomic *loci* which are known *to* have reduced penetrance (16p13.11, 16p11.2, and 22q11.2)*.* The inheritance status could not be determined in 25 cases.

In 47 patients (24 novel cases), the PCNVs overlapped with chromosomal regions associated with known genomic disorders, and, among them, 35 patients were detected with PCNVs at 10 *loci* that were recurrent (same breakpoints) or overlapping in 2 or more unrelated samples (Fig. [3](#Fig3){ref-type="fig"}). We found 23 cases with deletions known to cause a syndromic obesity phenotype: 1p36 (*n* = 5), 1p21.3 (*n* = 2), 2p25.3 (*n* = 1), 2q37 (*n* = 5), 6q16 (*n* = 1), 9q34.3 (*n* = 1), 16p11.2 breakpoint (BP) 2--3 (*n* = 1), 16p11.2 BP 4--5 (*n* = 1), and 17p11.2 (*n* = 5). The recurrent translocation t(8;12)(p23.1;p13.31) found in patient 18 is also known to be involved in the pathogenesis of syndromic obesity. In addition, 2 rare deletions at chromosomes 13q12.3 (patient 24) and 19p13.12 (patient 37) overlapped with deletions of different sizes in patients from the literature and the DECIPHER database who were obese (Fig. [4](#Fig4){ref-type="fig"}). Mapping of the shortest region of overlap (SRO) in these cases exposed a 660-kb interval at 13q12.3 (chr13:30,880,255--31,540,272 bp, hg19; Fig. [4a](#Fig4){ref-type="fig"}) comprising 5 genes (*KATNAL1*, *LINC00426*, *HMGB1*, *USPL1*, *ALOX5AP*, and *MEDAG*), and a 440-kb interval at 19p13.12 (chr19:15,052,889--15,492,848 bp, hg19; Fig. [4b](#Fig4){ref-type="fig"}) comprising 9 genes (*SLC1A6*, *CCDC105*, *CASP14*, *SYDE1*, *ILVBL NOTCH3*, *EPHX3*, *BRD4*, and *AKAP8*).Fig. 3Known genomic imbalance disorders detected in patients. Imbalances that are known to be causal for syndromic obesity are indicated (stars). The genes in parentheses are identifiers of genomic locations. WBS: William-Beuren syndrome; SMS: Smith-Magenis syndrome; DG: DiGeorge syndrome; KS: Kleefstra syndromeFig. 4Schematic alignment using the UCSC Genome Browser custom track tools (hg19) showing the regions of overlap between the deleted segments detected in (A) patient 24 (this study), DECIPHER case 282,282, and patients 1 and 2 of Bartholdi's study \[[@CR69]\]; (B) patient 38 (this study), DECIPHER case 255,743 and 265,764, and patient 1 of Bonaglia's study \[[@CR71]\]. The inheritance of the CNVs and the protein-coding genes located within them are shown. The inner light gray boxes show the smallest regions of overlapping deletions

In other 14 patients, the PCNVs did not overlap with a known genomic imbalance disorder but were de novo in 10 cases or of unknown origin (the remainder), and involved large and complex chromosomal imbalances. Among these, we found 4 PCNVs overlapping with previously identified obesity candidate *loci* (Fig. [5](#Fig5){ref-type="fig"}): a novel 22.3-Mb duplication of 3q11.2q13.31 (patient 49), a novel 11.6-Mb duplication of 13q11q12.3 (patient 53), a novel 8.5-Mb deletion of 13q33.2q34 (patient 57), and a 1-Mb duplication of band 14q11.2 (patient 58). Notably, the duplication region at 13q11q12.3 also overlaps with a smaller duplication present in our patient 19, who possessed a second large CNV at the 8p23.1 *locus*. The extent of overlap among our cases with those previously described CNVs is of about 2-Mb in band 3q13.31 (chr3:113,924,534--115,890,384 bp, hg19; Fig. [5a](#Fig5){ref-type="fig"}), 1.2-Mb in band 13q12.12 (chr13:23,706,634--24,910,765 bp, hg19; Fig. [5b](#Fig5){ref-type="fig"}), 2.4-Mb in band 13q34 (chr13:112,725,394--115,092,648 bp, hg19; Fig. [5c](#Fig5){ref-type="fig"}), and 827-kb in band 14q11.2 (chr14:21,424,185--22,250,879 bp, hg19; Fig. [5d](#Fig5){ref-type="fig"}). Candidate genes at these intervals are proposed in the discussion.Fig. 5Schematic alignment using the UCSC Genome Browser custom track tools (hg19) showing the regions of overlap between deleted (black) and duplicated (grey) segments detected in (**a**) patient 19 (this study), DECIPHER case 314,391 and brothers P1010 and P1011 of Vuillaume's study \[[@CR22]\]; (**b**) patients 19 and 53 (this study) and one individual described by Wang et al. \[[@CR75]\]; (**c**) patient 57 (this study), case P2007 of Vuillaume's study \[[@CR22]\] and families 1 and 2 of Reinstein's study \[[@CR21]\]; (**d**) patient 58 (this study), case P2023 of Vuillaume's study \[[@CR22]\], and one patient described by Terrone et al. \[[@CR14]\]. Vertical lines depict breakpoints that extended beyond the regions indicated here. The inheritance of the CNVs and the protein-coding genes located within them are shown. The inner light gray boxes show the smallest regions of overlap

### Likely pathogenic CNVs {#Sec10}

CNVs detected in 6 additional patients were classified as potentially clinically significant, including a de novo 340-kb duplication at 16p13.2 comprising the *USP7* gene implicated in a known deletion syndrome (OMIM \#616863), a 482-kb paternally inherited duplication of 17q11.2 partially overlapping the gene for neurofibromatosis type I (NF1), and an 1.1-Mb paternally inherited 20q11.2 duplication upstream of the *ASXL1* gene with a likely role in 20q11.2 duplication syndrome \[[@CR39]\]. The inheritance of 3 other CNVs could not be determined. The 3 CNVs were a 489-kb duplication in 21q22.13 including the ID gene *DYRK1A* (OMIM \#614104), a 703-kb deletion in 7q31.1 affecting the *IMMP2L*-*DOCK4* gene region implicated in IDDs \[[@CR40]\], and an intragenic deletion of the *ASTN2* gene at 9q33.1 which has also been implicated in susceptibility to IDDs \[[@CR41]\].

### Variants of uncertain significance {#Sec11}

In 15 patients, we detected CNVs that were classified as VUS. Of these, 2 were de novo events: a 222-kb 12q21.32 duplication including the *CEP290* gene whose mutations cause Bardet-Biedl syndrome (BBS14; OMIM \#615991), but which was not associated with previously reported pathogenicity, and a 385-kb 6q27 duplication affecting only three non-coding RNAs found in a patient who inherited a second large CNV. There were 3 VUS inherited from asymptomatic parents intersecting with genes within CNVs that have previously been implicated with disorders, such as *CACNA2D1* with epilepsy and ID \[[@CR42]\], and *MACROD2* and *LINGO2* with autism \[[@CR43], [@CR44]\]. Furthermore, 6 VUS (3 inherited and 3 unknown) contained morbid OMIM genes, including *NFIA*, *MPZ*, *PARK2*, *DPP6*, and *KANK1*. Additionally, 3 other cases (2 females and 1 male) inherited large chromosome X duplications from carrier mothers spanning several morbid OMIM genes but with no evidence for triplosensitivity phenotypes as determined by the ClinGen Dosage Sensitive Map ([http://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/](http://www.ncbi.nlm.nih.gov/projects/dbvar/clingen)) \[[@CR45]\].

### Likely benign CNVs {#Sec12}

We also observed 30 patients with CNVs that might represent benign variants. The observed CNVs were most often duplications and \< 300-kb in size. In all cases where it was possible to ascertain the parental status, variants were inherited from an asymptomatic parent. We found relevant genes lying within some of these CNVs. Examples of such genes include: *PTEN* in which mutations cause many different disorders including macrocephaly/autism syndrome (OMIM \#605309); *VPS13B* whose mutations cause Cohen syndrome characterized by truncal obesity, joint hypermobility and a pigmentary retinopathy (COH1; OMIM \#216550); *CIDEA* (OMIM 604440) with a role in regulating energy balance and adiposity; *ULK4* crucial to brain development with CNVs being identified as risk factor in schizophrenia \[[@CR46]\]; *KATNAL2* implicated as susceptibility gene of autism \[[@CR47]\].

Identification of candidate genes involved in obesity susceptibility {#Sec13}
--------------------------------------------------------------------

A total of 2684 genes were affected by the detected CNVs. Among these, 234 genes had some previously reported connection to obesity as determined by the overlap with genes from the T-HOD and HUGE database, as well as a gene list curated from literature \[[@CR33]\], and 172 overlapped with genes listed in the CNV morbidity map for IDDs \[[@CR34]\] (367 genes in total). Of particular interest are 87 genes that were intersected by different gene sets (Fig. [6](#Fig6){ref-type="fig"}). Notably, several known and candidate genes that have previously been implicated in syndromic obesity were retrieved by this candidate gene approach, including *SIM1* \[[@CR48]\], *SH2B1* \[[@CR49]\]*, PTBP2* \[[@CR38]\]*, PRLH* and *CAPN10* \[[@CR50]\], *ACP1* and *TMEM18* \[[@CR12]\]*, EHMT1* \[[@CR51]\]*,* and *GNB3* \[[@CR17]\]. Thus, these genes were considered as more likely to have a role in obesity susceptibility. Pathways analysis in Cytoscape using the plugin Reactome FI showed that the majority of these genes were related to metabolic pathways and small molecule metabolic process.Fig. 6shows 87 prioritized genes and their positions within PCNVs, but also likely PCNVs, VUS and benign CNVs (asterisk). Prioritized genes were retrieved by at least 2 independent gene sets, including obesity candidate genes collected from the T-HOD (Text-mined Hypertension, Obesity and Diabetes) and HUGE (Human Genome Epidemiology) database, a list of genes with evidence for playing a role in obesity curated from literature \[[@CR33]\], and genes in the CNV morbidity map for IDDs \[[@CR34]\]

PCNV rates by gender, age and level of obesity in children and adolescents {#Sec14}
--------------------------------------------------------------------------

For the purpose of this study, 208 obese children and adolescents with a BMI ≥95th percentile were considered based on a percentage above the 95th BMI percentile as moderately (\< 120% of the 95th percentile) and severely (≥120% of the 95th percentile) obese (Fig. [7a](#Fig7){ref-type="fig"}). This sample consisted predominantly of males (*n* = 123 or 59%) and children aged 2--9 years (*n* = 125 or 60%). The majority of patients were classified as severely obese (*n* = 160 or 77%). The prevalence of severe obesity was higher than moderate obesity for both gender and age groups (Fig. [7b](#Fig7){ref-type="fig"}) but there were statistically significantly more males than females with severe obesity (105 males, 55 females; Fisher's Exact test, *p* \< 0.01); this sex-related difference in obesity was observed in children but not in adolescents aged 10--19 years (Additional file [4](#MOESM4){ref-type="media"}: Table S4). Although a higher frequency of PCNVs was observed in females (*n* = 23 or 27%) compared with males (*n* = 24 or 20%), no statistically significantly differences were observed in the frequencies when compared by gender, age at the time of testing, and obesity severity (Fig. [7c and d](#Fig7){ref-type="fig"}; Additional file [5](#MOESM5){ref-type="media"}: Table S5). In boys, the prevalence of PCNVs was greater in the severe obesity group (20% vs. 17%), particularly among children aged 2--9 years (18% vs. 11%), but was similar at adolescence (22%). In girls, the prevalence of PCNVs was greater among the moderate obesity group (35% vs. 30%), particularly among children aged 2--9 years (35% vs. 25%), and correlated inversely in adolescents (26% severe vs. 20% moderate obesity).Fig. 7(A) Frequencies of children and adolescents in the whole cohort with BMI ≥ 95th percentile stratified by gender (males and females), age groups (2--9 years and 10--19 years), and level of obesity (moderate and severe). (B) Sex- and age-related differences of children and adolescents in the whole cohort by level of obesity. (C, D) same comparisons in children and adolescents with PCNVs. The numbers in parentheses indicate the total number of patients in each group. Definition of moderate and severe obesity was based on the BMI below or above 120% of the 95th percentile. *P*-values for the Fisher's exact test are shown

Discussion {#Sec15}
==========

This is the second study describing the use of CMA in patients ascertained for syndromic obesity, the largest published to date and also the first in a Brazilian cohort. We identified PCNVs in 22% of patients (68 pathogenic events in 61/279 subjects; Table [3](#Tab3){ref-type="table"}), which is similar to the yield reported by Vuillaume et al. in microarray studies with 100 patients with syndromic obesity \[[@CR22]\]. The prevalence of PCNVs in children and adolescents did not differ significantly between gender and age groups, and obesity severity (Fig. [7](#Fig7){ref-type="fig"}). Nevertheless, females had a higher detection rate of PCNVs in comparison to males (27% females and 20% males; overall), with the highest differences (35% females and 11% males) found in the younger age group (2--9 years) with less severe grades of obesity (BMI \< 1.2 x 95th percentile). Whilst no single phenotypic feature could be investigated for association with PCNV risk, due to the absence of comprehensively phenotyping of patients, phenotype-phenotype correlation analysis between cases with and without PCNVs identified 12 pairs of phenotypes that were significantly associated with the presence of PCNVs and combining hypotonia, language impairments, abnormalities of the external genitalia, and eye/vision problems at its core. Of note, patients in our cohort were almost 10 times more likely to manifest macrocephaly as compared to microcephaly. Even though 33% of macrocephalic patients displayed PCNVs, macrocephaly did not associate with the presence of PCNVs.

In the current study, we have identified known genomic imbalance disorders in 47 patients, and, of them, 35 patients (13%) carry overlapping and recurrent CNVs (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). In our cohort, imbalances that are known to be causal for syndromic obesity were observed in 23 patients (8.2%). The most commonly identified syndromic forms of obesity were deletions of the chromosomal regions 1p36, 2q37 and 17p11.2, which collectively represented 5.4% of all cases, followed by microdeletions of the 1p21.3 region (2 cases). In 6 other syndromic obesity *loci* (2p25.3, 6q16, 9q34, 16p11.2 proximal and distal, 12p13.31), CNVs were found only in one unrelated individual. The identification of CNVs overlapping *loci* previously shown to be involved in syndromic obesity further implicates them as risk factors for obesity. As previously mentioned, *SH2B1*, *SIM1*, *PTBP2, PRLH*, *CAPN10, ACP1, TMEM18, EHMT1,* and *GNB3* are relevant candidate and known genes for obesity within these regions (Fig. [6](#Fig6){ref-type="fig"}), and *POU3F2* \[[@CR20]\], *HDAC4* \[[@CR50]\], *MYT1L* \[[@CR52]\], and *RAI1* \[[@CR53]\] were also candidate genes identified in these *loci*. Moreover, our gene prioritization analysis identified 20 new genes of interest to obesity overlapping these CNVs, among which we highlight the potential importance of *TAS1R3*, encoding a taste receptor differentially expressed in obese mice \[[@CR54]\]. This gene maps within the common deleted region of patients with distal 1p36 deletion.

In addition to the above, we identified 4 patients with recurrent deletions at the 22q11.2 DiGeorge syndrome (DS) region (we also found a patient with duplication of the same region), 4 patients with distal 22q11.2 recurrent deletions, and 3 patients with overlapping deletions at 9p terminal. As these CNVs arise in more than 2 unrelated individuals, we implicate them as novel *loci* with a potential role in obesity susceptibility. A link between the 22q11.2 region with obesity is also supported by previous works showing that 22q11.2DS deletion carriers have increased rates of obesity \[[@CR55]--[@CR57]\], as well as reports of patients presenting childhood obesity with hyperphagia \[[@CR58], [@CR59]\]. Overweight and obesity (with or without hyperphagia) have also been described in a number of patients with distal 22q11.2 deletions \[[@CR60]--[@CR63]\]. We identified 3 genes at 22q11.2 (*TBX1*, *COMT* and *MAPK1*) that could confer susceptibility to obesity (Fig. [6](#Fig6){ref-type="fig"}). Although obesity is not a reported feature of deletion 9p syndrome, weight ≥ 90th percentile at birth or in childhood was documented in 4 of a series of 10 patients with distal deletions of 9p \[[@CR64]\], further emphasizing the potential importance of this region. Additionally, we recently detected a deletion at 9p24.3p24.2 in one further patient with syndromic obesity using multiplex ligation-probe amplification (unpublished data from our laboratory). The *VLDLR*, *IL33* and *PTPRD* genes were identified as the most interesting genes for obesity-susceptibility within 9p24 (Fig. [6](#Fig6){ref-type="fig"}). Furthermore, we detected 2 patients with Williams-Beuren syndrome (WBS) 7q11.23 deletions. This region was already shown to be associated with several endocrine and metabolic problems including hypothyroidism, hypercalcemia, obesity and diabetes \[[@CR65], [@CR66]\]. Two genes related to obesity, *STX1A* and *RFC2*, map to this CNV interval (Fig. [6](#Fig6){ref-type="fig"}).

In this study we discovered recurrent CNVs at 1q21.1 and 16p13.1, which are known predisposing factors to IDDs reported sometimes in patients exhibiting obesity \[[@CR67], [@CR68]\]. Moreover, CNVs at these *loci* were also documented in a cohort study of syndromic obesity \[[@CR22]\]. We also discovered other CNVs overlapping *loci* involved in syndromic obesity cases from the literature and DECIPHER. For instance, patient 24 carry a deletion overlapping the critical region of the 13q12.3 microdeletion syndrome described by Bartholdi et al. in 3 unrelated patients, two of whom with obesity \[[@CR69]\]. This deletion was further associated with obesity in a patient from DECHIPER (case 282,282). Five genes map to the common CNV interval (Fig. [4a](#Fig4){ref-type="fig"}), among them *ALOX5AP* whose expression was linked to obesity and insulin resistance \[[@CR70]\]. Likewise, patient 38 carry a deletion at 19p13.12 partially overlapping with those reported in 3 patients from literature, one of them with obesity \[[@CR71]\]. We found 2 other patients in DECIPHER with deletions at this *locus* in addition to obesity (cases 255,743 and 265,764). These cases share a 440-kb SRO encompassing 9 genes, including *NOTCH3* (Fig. [4b](#Fig4){ref-type="fig"}). The Notch signaling has recently emerged as a key player in regulating metabolism \[[@CR72]\]. We also identified a case of 19p13.2 duplication involving the *NFIX* gene associated with a Sotos syndrome-like phenotype \[[@CR73]\]. This CNV was associated with a 430-kb 9p22.1 duplication that encompassed the entire *PLIN2* gene, which is involved in the control of energy balance \[[@CR74]\]. Notably, CNV in this gene has previously been identified in a patient with syndromic obesity \[[@CR22]\].

Other than CNVs overlapping known genomic disorders *loci*, 14 patients had other chromosomal defects that are known to be clinically relevant, among which 4 overlapped with *loci* previously implicated in obesity. The distal portion of the 3q11.2q13.31 duplication in patient 49 (Fig. [5a](#Fig5){ref-type="fig"}) partially overlaps with a 2.76-Mb 3q13.31 duplication found in 2 brothers with syndromic obesity \[[@CR22]\], and with a 9.8-Mb 3q13.13q13.32 duplication reported in association with obesity from DECIPHER (case 314,391). The common region of overlap involves 5 genes and among them *ZBTB20* is implicated in Primrose syndrome associated with several endocrine features and obesity (OMIM \#259050). The large 13q11q12.3 duplication in our patient 53 (Fig. [5b](#Fig5){ref-type="fig"}) overlaps with a 1.2-Mb 13q12.12 duplication also found in our patient 19 and with another 2-Mb 13q12.11q12.12 duplication detected among cases with moderate and extreme obesity \[[@CR75]\]. This region involves the gene *SGCG* with expression in adipose tissues and associated with type 2 diabetes \[[@CR76]\]. Patient 57 carry an 8.5-Mb 13q33.2q34 deletion encompassing the ID gene *CHAMP1* (Fig. [5c](#Fig5){ref-type="fig"}), which partially overlaps with deletions at 13q34 found in 6 other patients with syndromic obesity reported by Vuillaume et al. \[[@CR22]\] and Reinstein et al. \[[@CR21]\]. Of interest, the deleted region in each of the 7 cases overlaps the obesity-associated gene *GAS6* \[[@CR77]\]. The 14q11.2 microduplication found in our patient 58 (Fig. [5d](#Fig5){ref-type="fig"}), including the *SUPT16H* and *CHD8* genes, was also identified in one patient with syndromic obesity reported by Vuillaume et al. \[[@CR16]\]. No candidate genes for obesity were associated with this *locus*. Although there is one case of 14q11.2 deletion that was reported with severe obesity, it included a large more proximal segment of 14q11.2, which contains a strong obesity candidate gene \[[@CR14]\].

Finally, in a total of 51 patients the CNVs were classified as potentially pathogenic (2.1%), VUS (4.7%) or likely benign variants (11.5%). Overall, a number of interesting genes that could play a role in obesity susceptibility have been identified within these CNVs (e.g. *ASTN2, APOA2*, *PARK2*, *LINGO2*, *PLCB1*, *PTEN*, and *CIDEA*). More importantly, we identified a new and de novo 340-kb 16p13.2 duplication that encompasses the entire *USP7* gene. Although its pathogenicity is not certain, since similar duplications have not been reported in the literature, there is one reported patient with larger duplication at the *USP7* locus presenting with severe early-onset obesity and hyperphagia \[[@CR78]\]. Of note, USP7 has been identified as an integral component of MAGEL2 and TRIM27 ubiquitin ligase complex, which plays an important role in hypothalamic function \[[@CR79]\]. Moreover, deletion or mutation of *USP7* has been shown to result in a neurodevelopmental disorder with overlapping symptoms to Schaaf-Yang syndrome (OMIM \#615547), caused by mutations of *MAGEL2* \[[@CR78]\]. There are 5 de novo duplication events overlapping *USP7* (400-kb to 1.2-Mb) reported in DECIPHER with no additional changes detected. These included 3 patients (cases 269,501, 281,449 and 258,037) with delayed speech and language development as common features and 2 patients (cases 254,000 and 267,094) with no phenotypic description. One of the limitations of our study is that additional independent risk factors were not considered, including unidentified genetic factors and those being epigenetic, environmental, or stochastic in origin. Future investigations of genes within disease-specific CNVs detected in the present cohort are also needed. Future directions will involve whole exome sequencing (WES) in patients that did not reach a diagnosis to estimate the contribution of single gene mutations in the genetic causation of syndromic obesity. This will allow isolate genes that cause or may affect susceptibility to obesity in humans, advancing our understanding of the molecular mechanisms involved in body weight regulation and provide clues for therapeutic intervention in obesity.

Conclusion {#Sec16}
==========

Understanding the genetics of obesity has proven difficult. Although it is likely that not all of the PCNVs detected in the current study are directly causative of obesity, we found that 23/279 (8.2%) of our patients carried rare CNVs at 10 *loci* already known to increase the risk of obesity. We identified 3 patients with overlapping deletions at 9p terminal, 4 patients with deletions of 22q11.2DS and 4 patients with deletions at distal 22q11.2, which thus emerge as new putative obesity-susceptibility *loci*. In addition, we found that CNVs in at least 6 other cases overlapped with *loci* previously implicated in syndromic obesity, including a new patient with deletion at chromosome 13q34. This *locus* is particularly interesting because our new case brings to 7 the number of patients in whom such defects have been described in association with obesity. Overall, we found CNVs that further implicate genes previously associated with obesity such as *PTBP2*, *TMEM18*, *MYT1L*, *POU3F2*, *SIM1*, *SH2B1* and *GNB3*, and also identified other potentially relevant candidate genes including *TAS1R3*, *ALOX5AP*, and *GAS6.* Our study highlights the significant value of chromosomal microarrays in providing not only a genetic diagnosis for syndromic causes of obesity but in uncovering genes relevant to human obesity.
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